| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | 12.16% | B of A Securities | → $63 | Initiates Coverage On | → Neutral |
| 07/25/2023 | 24.62% | Jefferies | → $70 | Reinstates | Buy → Buy |
| 05/17/2023 | -21.67% | Wells Fargo | $40 → $44 | Maintains | Equal-Weight |
| 10/25/2022 | -28.79% | Piper Sandler | $43 → $40 | Maintains | Overweight |
| 10/21/2022 | -35.91% | Jefferies | → $36 | Assumes | → Buy |
| 07/29/2022 | -21.67% | Capital One | → $44 | Initiates Coverage On | → Overweight |
| 03/15/2022 | -43.03% | Wells Fargo | $23 → $32 | Maintains | Equal-Weight |
| 03/11/2022 | -37.69% | Piper Sandler | $28 → $35 | Maintains | Overweight |
| 01/07/2022 | -50.15% | Piper Sandler | $21 → $28 | Upgrades | Neutral → Overweight |
| 03/17/2021 | -64.39% | Wells Fargo | $21 → $20 | Maintains | Equal-Weight |
| 01/08/2021 | -62.61% | Wells Fargo | → $21 | Downgrades | Overweight → Equal-Weight |
| 10/05/2020 | — | Northland Capital Markets | Upgrades | Market Perform → Outperform | |
| 07/09/2020 | -59.05% | Northland Capital Markets | → $23 | Downgrades | Outperform → Market Perform |
| 05/11/2020 | -62.61% | BMO Capital | $20 → $21 | Maintains | Market Perform |
| 03/13/2019 | — | Needham | Downgrades | Buy → Hold |
What is the target price for Amphastar Pharma (AMPH)?
The latest price target for Amphastar Pharma (NASDAQ: AMPH) was reported by B of A Securities on November 17, 2023. The analyst firm set a price target for $63.00 expecting AMPH to rise to within 12 months (a possible 12.16% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amphastar Pharma (AMPH)?
The latest analyst rating for Amphastar Pharma (NASDAQ: AMPH) was provided by B of A Securities, and Amphastar Pharma initiated their neutral rating.
When is the next analyst rating going to be posted or updated for Amphastar Pharma (AMPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amphastar Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amphastar Pharma was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
Is the Analyst Rating Amphastar Pharma (AMPH) correct?
While ratings are subjective and will change, the latest Amphastar Pharma (AMPH) rating was a initiated with a price target of $0.00 to $63.00. The current price Amphastar Pharma (AMPH) is trading at is $56.17, which is within the analyst's predicted range.